Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Re: Piet Ost, Shankar Siva, Sigmund Brabrabd, et al. Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V–STORM): A Phase 2, Open-label, Randomised Controlled Trial. Lancet Oncol 2025;26:695–706. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456925001865?dgcid=rss_sd_all
Re: Piet Ost, Shankar Siva, Sigmund Brabrabd, et al. Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V–STORM): A Phase 2, Open-label, Randomised Controlled Trial. Lancet Oncol 2025;26:695–706. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456925001865?dgcid=rss_sd_all
“Re: Piet Ost, Shankar Siva, Sigmund Brabrabd, et al. Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V–STORM): A Phase 2, Open-label, Randomised Controlled Trial. Lancet Oncol 2025;26:695–706.” European Urology Focus.
@article{article116732,
title = {Re: Piet Ost, Shankar Siva, Sigmund Brabrabd, et al. Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V–STORM): A Phase 2, Open-label, Randomised Controlled Trial. Lancet Oncol 2025;26:695–706},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456925001865?dgcid=rss_sd_all}
}